The 55-year-old was the first to receive personalised treatment that gave hope to millions of patients
Elliot FabveyThe 55-year-old university professor and father of four became the first patient to receive an experimental personalised vaccine aimed at preventing bowel cancer from returning. The vaccine, developed with mRNA (messenger RNA) technology – the same as that used in vaccines against Covid – has the potential to revolutionise oncology treatment.
On Friday (31), the National Health Service UK The (NHS) announced the detailed news on Saturday (1st) by BioNTech SE, the German biotechnology company responsible for developing the vaccine. The presentation took place during the annual Clinical Oncology Conference ChicagoWe We,
The clinical trials aim to evaluate the effectiveness and safety of treatments to prevent tumors from relapsing in patients with severe cases of the disease like Fabve. Asymptomatic, he was diagnosed with invasive colorectal cancer in a routine examination in 2023. The professor underwent surgery and chemotherapy until the tumor symptoms disappeared and volunteered for the clinical trial. According to a statement, the NHS hopes to recruit more than a thousand people to take part in the trials in the coming months.
“If [o estudo clínico] is successful, [a vacina contra o câncer] I can help thousands, if not millions, of people so they can have hope and not go through what I went through.”Fabve said in a note.
The clinical trial that Phebve is part of is one of several NHS-funded trials across the country to treat various types of tumors. These trials are part of a new oncology vaccine launch platform from the English national service, which currently brings together more than 30 hospitals across the country. England For patient admission and monitoring.
Vaccine Development
Vaccines used in colorectal cancer trials are developed by analyzing a patient’s tumor to identify specific mutations. With this information, doctors create a personalized vaccine.
These vaccines are designed to produce an immune response that can prevent cancer from returning after surgery on the primary tumor by stimulating the patient’s immune system to recognize and destroy any remaining cancer cells. In late April, another Briton was vaccinated with the first vaccine of its kind against skin cancer.
These vaccines are called so because they teach the immune system to fight cancer in the same way that vaccines teach us to defend ourselves against viruses and bacteria. However, they are not designed to prevent the development of a primary cancer.
Jointly developed by biopharmaceutical companies BioNTech and Genentech, members of the Roche Group, these immunizers have not yet been approved by regulatory bodies and are, therefore, not available outside of the clinical research environment.
*Text under the supervision of Tomaz Belluomini
